antibody

Rabbit anti TGF-beta 1 Polyclonal

MBS551006

0.1 mg

280 USD

polyclonal

rabbit

nonconjugated

human, mouse, rat

western blot, ELISA, immunohistochemistry, enzyme immunoassay

Antibody

Rabbit anti TGF-beta 1 Polyclonal

TGF-beta 1

Rabbit anti TGFB1 Polyclonal purified; tgfb1; tgf-b1; polyclonal; PAb

transforming growth factor beta-1; Transforming growth factor beta-1

TGFB1

TGF beta

TGFB1; TGFB; TGF-beta-1; LAP

TGFB1_HUMAN

Polyclonal

IgG

Rabbit

Human, Mouse, Rat

390

Serum IgG fraction was purified by Protein G affinity chromatography.

Lyophilized from sterile filtered PBS solution at a concentration of 1mg/ml.

The lyophilized antibody is stable for at least 1 year from date of receipt at -20 degree C. Upon reconstitution, this antibody can be stored in working aliquots at 2 degree - 8 degree C for one month, or at -20 degree C for six months without detectable loss of activity. Avoid repeated freeze/thaw cycles. Shelf Life: >12 months

Western Blot (WB), IHC (Immunohistochemistry), ELISA (EIA)

ELISA: Use at a concentration range of 1-2ug/ml. Western blot:A suitable range of concentrations of this antibody for WB detection is 2-10 ug/ml. IHC: A suitable range of concentrations of this antibody for IHC is 2-10 ug/ml. Immunohistochemical analysis of TGF beta 1 expression in rat articular cartilage tissue. It was used as primary antibody dilution 1:500. Immunohistochemical analysis of TGF beta 1 expression in human pancreatic tissue. It was used as primary antibody, dilution 1:500.

Source Note: Polyclonal TGF-beta 1 antibody was produced from sera of rabbits immunized with synthetic protein containing TGF-beta 1 antigenic determinants.

Reconstitution: A quick spin of the vial followed by reconstitution in distilled water. This solution can then be diluted into other buffers

Polyclonal

TGF-beta is the prototype of a protein family known as the TGF-beta superfamily. This family includes Inhibins, Activin A, MIS (M llerian inhibiting substance), BMP (bone morphogenetic proteins), dpp (decapentaplegic) and Vg-1. Type 1 receptors and type 2 receptors have a molecular mass of 53 and 75 kDa, respectively. Signaling through the receptor requires heterodimeric complexes between both types of receptors. The type 2 receptor has been shown to bind the ligand, but it is incapable of mediating TGF- beta responses in the absence of the type 1 receptor. The type 1 receptor is expressed predominantly in hematopoietic progenitor cells. The type 2 receptor encodes a protein with an intracellular domain that functions as a serine/threonine kinase. TGF-beta is the most potent known growth inhibitor for normal and transformed epithelial cells, endothelial cells, fibroblasts, neuronal cells, lymphoid cells and other hematopoietic cell types. TGF-beta inhibits the proliferation of T- lymphocytes by down- regulating predominantly IL- 2 mediated proliferative signals. It also inhibits the growth of natural killer cells in vivo and deactivates macrophages. TGF-beta blocks the antitumor activity mediated in vivo by IL-2 and transferred lymphokine- activated or tumor infiltrating lymphocytes.

63025222

NP_000651.3

NM_000660.4

P01137

44,341 Da

ACE Inhibitor Pathway 198763!!ALK1 Signaling Events Pathway 137968!!Adipogenesis Pathway 198832!!Amoebiasis Pathway 167324!!Amoebiasis Pathway 167191!!Cell Cycle Pathway 198811!!Cell Cycle Pathway 83054!!Cell Cycle Pathway 463!!Chagas Disease (American Trypanosomiasis) Pathway 147809!!Chagas Disease (American Trypanosomiasis) Pathway 147795

Function: Multifunctional protein that controls proliferation, differentiation and other functions in many cell types. Many cells synthesize TGFB1 and have specific receptors for it. It positively and negatively regulates many other growth factors. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. Subunit structure: Homodimer; disulfide-linked, or heterodimer with TGFB2 . By similarity. Secreted and stored as a biologically inactive form in the extracellular matrix in a 290 kDa complex (large latent TGF-beta1 complex) containing the TGFB1 homodimer, the latency-associated peptide (LAP), and the latent TGFB1 binding protein-1 (LTBP1). The complex without LTBP1 is known as the'small latent TGF-beta1 complex'. Dissociation of the TGFB1 from LAP is required for growth factor activation and biological activity. Release of the large latent TGF-beta1 complex from the extracellular matrix is carried out by the matrix metalloproteinase MMP3 . By similarity. May interact with THSD4; this interaction may lead to sequestration by FBN1 microfibril assembly and attenuation of TGFB signaling. Interacts with the serine proteases, HTRA1 and HTRA3: the interaction with either inhibits TGFB1-mediated signaling. The HTRA protease activity is required for this inhibition . By similarity. Latency-associated peptide interacts with NREP; the interaction results in a decrease in TGFB1 autoinduction . By similarity. Interacts with CD109, DPT and ASPN. Ref.12 Ref.15 Ref.17. Subcellular location: Secreted extracellular space extracellular matrix Ref.17. Tissue specificity: Highly expressed in bone. Abundantly expressed in articular cartilage and chondrocytes and is increased in osteoarthritis (OA). Co-localizes with ASPN in chondrocytes within OA lesions of articular cartilage. Ref.13 Ref.17. Induction: Activated in vitro at pH below 3.5 and over 12.5. Domain: The 'straitjacket' and 'arm' domains encircle the growth factor monomers and are fastened together by strong bonding between Lys-56 and Tyr-103/Tyr-104. Activation of TGF-beta1 requires the binding of integrin alpha-V to an RGD sequence in the prodomain and exertion of force on this domain, which is held in the extracellular matrix by latent TGF-beta binding proteins. The sheer physical force unfastens the straitjacket and releases the active growth factor dimer . By similarity. Post-translational modification: Glycosylated.The precursor is cleaved into mature TGF-beta-1 and LAP, which remains non-covalently linked to mature TGF-beta-1 rendering it inactive. Polymorphism: In post-menopausal Japanese women, the frequency of Leu-10 is higher in subjects with osteoporosis than in controls. Involvement in disease: Camurati-Engelmann disease (CE) [MIM:131300]: Autosomal dominant disorder characterized by hyperostosis and sclerosis of the diaphyses of long bones. The disease typically presents in early childhood with pain, muscular weakness and waddling gait, and in some cases other features such as exophthalmos, facial paralysis, hearing difficulties and loss of vision.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.23 Ref.24 Ref.26 Ref.27 Ref.28. Sequence similarities: Belongs to the TGF-beta family.

0.1 mg

280 USD